7/29/14 1 Robert C. Holleman, Jr., MD Associate Professor of Clinical Pediatrics Pediatric Nephrology and Hypertension USC School of Medicine PEDIATRIC HYPERTENSION Disclosures ! I have no financial or industry relationships to disclose ! I will not be discussing any off lable medications Objectives/Questions ! How do we measure and define HTN in children? ! Who should be screened? ! What are the most common causes of pediatric HTN? ! What is the appropriate diagnostic plan? ! When do we treat with medication? ! What drug(s) do we choose? ! What is the utility of 24hr ambulatory BP monitoring?
23
Embed
Robert C. Holleman, Jr., MD - Pediatric Hypertension A ...
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
7/29/14
1
Robert C. Holleman, Jr., MD Associate Professor of Clinical Pediatrics Pediatric Nephrology and Hypertension
USC School of Medicine
PEDIATRIC HYPERTENSION
Disclosures
!! I have no financial or industry relationships to disclose
!! I will not be discussing any off lable medications
Objectives/Questions !! How do we measure and define HTN in children? !! Who should be screened? !! What are the most common causes of pediatric
HTN? !! What is the appropriate diagnostic plan? !! When do we treat with medication? !! What drug(s) do we choose? !! What is the utility of 24hr ambulatory BP
monitoring?
7/29/14
2
Pediatric Hypertension
Can we still blame the kidney?
"
A primary care problem?
Blood Pressure Measurement #! Arm/cuff size
- Bladder width > 40% mid arm circumference
- Bladder length 80-100% mid arm circumference
#! Comfort/Cooperation #! At rest for 3-5 minutes #! Clothing out of the way #! Right arm, heart level #! At least 2 readings
#! Replaces “borderline” or “high normal” BP #! BP > 90th %tile but < 95th %tile #! Adolescents with BP > 120/80 #! Implement healthy lifestyle changes and
identify other cardiovascular disease risk factors
#! At risk for future HTN so follow up is key
Adolescent Example #! 17 year old male #! Height: 95th %tile #! Average BP: 135/83
90th %tile: 136/84 95th %tile: 140/89
Reference Values
Normal BP by standard definition but BP > 120/80
Recommendation of the Fourth Report is to classify this patient as pre-hypertension
Difficulty in reconciling outcome based adult data with normative based pediatric data
7/29/14
5
BP Screening: Argument For #! HTN is the most common primary diagnosis in
the U.S. with healthcare costs in the billions #! High BP in adults is an independent risk factor
for the development of cardiovascular disease, stroke, and chronic kidney disease
#! More than 7 million premature deaths worldwide annually in adults attributable to HTN
#! HTN accounts for 40% of cardiovascular mortality, more than any other risk factor including smoking
BP Screening: Argument For #! BP tracking: childhood BP predicts adult BP
$$ Childhood HTN is the strongest predictor of adult HTN $$ BP at the 90th %tile in childhood increases risk of adult HTN x 2.4
#! Childhood HTN is associated with increased carotid intima-media thickness, endothelial dysfunction and increased vascular stiffness " markers for adult atherosclerosis
#! The rationale for childhood BP screening as an important strategy for increasing health and decreasing cardiovascular mortality in adults has been endorsed by:
$$ American Academy of Pediatrics $$ European Society of Hypertension $$ American Heart Association $$ National Heart Lung and Blood Institute
BP Screening: Argument Against
#! Lack of prospective, longitudinal clinical studies #! Potential harm of screening: stress, anxiety, labeling #! Potential harm of unnecessary testing and treatment #! Prevalence inadequate to justify widespread screening
“current evidence is insufficient to assess the balance of benefits and harms of screening for primary hypertension in asymptomatic
children and adolescents to prevent subsequent cardiovascular disease in childhood or adulthood.”
- Moyer V, Pediatrics, 132(5), 2013
U.S. Preventive Services Task Force (USPSTF)
7/29/14
6
BP Screening: current practice
Type of Visit 2000-2009 2000-2001 2008-2009
All Visits 35% 26% 41%
Preventive Care Visits 67% 51% 71%
Preventive Care Visits + Overweight/Obese 84% 71% 81%
Hypertension Screening During Ambulatory Pediatric Visits in the United States, 2000-2009
- Shapiro DJ et al, Pediatrics, 2012
Data from the National Ambulatory Medical Care Survey and the National Hospital Ambulatory Medical Care Survey
#! 93,534 ambulatory visits for children age 3 to 18 sampled #! BP screening more likely in older kids and kids who were overweight/obese #! Non factors in screening frequency included: race, gender, region, practice
setting and use of an EMR
Who should be screened and how? #! All children > 3 years of age at least annually #! Preferred method is auscultation with an
age/size appropriate cuff #! Abnormal BP obtained by oscillometric device
should be repeated by auscultation #! Elevated BP must be confirmed on repeat
visits before diagnosing HTN
The Fourth Report on the Diagnosis, Evaluation, and Treatment
of High Blood Pressure in Children and Adolescents
Conditions requiring BP screening prior to age 3 years #! History of prematurity, very low birth weight,
or complicated NICU stay #! Congenital heart, renal, or urologic disease #! Recurrent UTIs, hematuria, proteinuria #! Solid organ or bone marrow transplant #! Treatment with drugs known to cause " BP #! Systemic disease associated with HTN #! Evidence of increased intracranial pressure
The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents
7/29/14
7
Epidemiology #! Estimated pediatric prevalence 5% #! Higher in minority populations #! > #! BP # BMI #! Essential HTN is the most prevalent
adolescents are obese #! The relationship between BP and
weight begins as early as age 5yrs #! HTN is three times more common
in obese children #! Obesity is an independent risk
factor for other cardiovascular morbidity " ! insulin resistance/type II DM ! dyslipidemia ! LVH
Obesity related HTN
The Perils of Insulin
" SNS Altered vascular
reactivity
Na retention " RAS
HYPERTENSION
%
Etiology of Pediatric HTN
#! No identifiable cause #! Incidence "’s with age #! Positive family history #! HTN usually less severe #! Closely related to BMI #! Stress sensitive #! Strongly predictive of
& greater “salt sensitivity” in African Americans and obese pts
#! “DASH” diet & more fruits, veggies, and low fat dairy & theoretical benefit from K+, Ca++, and Mg++
#! Avoid caffeine/energy drinks #! Address dietary cholesterol and fat as well
as foods with high glycemic load when appropriate
The Benefits of Exercise
#! % sympathetic tone and SVR #! Contributes to weight loss #! Lowers insulin levels #! For most kids with
HTN…”it’s ok to play”
Lowers blood pressure
Treatment Algorithm Risk Assessment
#! Family History: HTN, CVD, CVA
#! Obesity #! Dyslipidemia #! Hyperinsulinemia
#! LVH #! Retinopathy #! Proteinuria or
microalbuminuria #! Chronic disease:
- DM, CKD
Co-Morbid Risk Factors
Target Organ Dz (TOD) Chronic Disease
7/29/14
16
Target Organ Disease (TOD)
Treatment Algorithm
No Risk Factors No TOD/chronic dz
Pre-HTN Stage 1 HTN Stage 2 HTN
TLC TLC TLC + Drug Tx
Treatment Algorithm
(+) Risk Factors No TOD/chronic dz
Pre-HTN Stage 1 HTN Stage 2 HTN
TLC TLC Drug tx if no improvement
in 6-12 months
TLC + Drug Tx
7/29/14
17
Treatment Algorithm
(+) TOD/Chronic Dz
Pre-HTN Stage 1 HTN Stage 2 HTN
TLC + Drug Tx
TLC + Drug Tx
TLC + Drug Tx
Drug Therapy - Obstacles
#! Lack of pediatric trials and dosage guidelines
#! Lack of age appropriate formulations
#! Lack of safety information
Important Legislation #! Food and Drug Administration Modernization
Act (FDAMA) in 1997 FDA will identify drugs that may benefit children and request
drug companies to conduct pediatric trials
#! Best Pharmaceuticals for Children Act (BPCA) in 2002 Established Office of Pediatric Therapeutics at FDA Provides a process for off-patent drug development
#! Pediatric Research Equity Act (PREA) in 2003 All new drug applications must contain a pediatric assessment
unless the manufacturer obtains a waiver
7/29/14
18
Drug Therapy - Choices #! ACE inhibitors #! Ca channel blockers #! Diuretics #! Angiotensin receptor
blockers (ARBs) #! Sympathetic
antagonists - # and/or $ #! Other
Angiotensin Converting Enzyme Inhibitors (ACEI)
#! Mechanism: Ang I Ang II #! Adverse effects: cough, hypotension, %GFR,
#! Diverse group of drugs: & THIAZIDES + #1 for chronic HTN; useful as 2nd agent or
occasionally as monotherapy; Chlorothiazide, HCTZ & LOOP agents + acute HTN in certain settings, refractory volume overload; Furosemide, Bumetanide & K+ SPARING + weak diuretics; use for mineralocorticoid excess or as 2nd diuretic if hypoK; Spironolactone, Amiloride
Angiotensin Receptor Blockers #! Mechanism: Prevents binding of ang II to
the type I receptor (vascular smooth muscle and adrenal gland) '
% vasoconstriction % aldosterone #! Adverse effects: same as ACEI except
cough #! Contraindications: same as ACEI #! The “tans”: Losartan, Irbesartan, Valsartan #! General: less pediatric experience;
adjunctive antiproteinuric effect with ACEI
Sympathetic Antagonists
#! % CO, PVR, and renin #! Avoid in pts with RAD,
IDDM, heart block #! May cause fatigue,
dizziness, orthostasis, sexual dysfunction, dyslipidemia
#! Propranolol, Atenolol, Metoprolol, Labetalol
#! % PVR #! May cause dizziness, HA,
fatigue, palpitations, “first dose effect”
#! Seldom used in kids; used in pheo and ? utility in dysmetabolic synd